Talazoparib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), CHUIKYO (Japan) and G-BA (Germany), among others, recommended or restricted talazoparib, while AOTMIT (Poland) and DMC (Denmark) did not recommend it.
Assessment has run over 7.1 years, from 2019 at PBAC (Australia) to 11 Aug 2026 at AIFA (Italy).
CIPM (Spain) changed its position: not recommended on 6 May 2021, recommended by 20 Nov 2024, after a resubmission.
No assessment is on file from HAS (France) and PHARMAC (New Zealand), each among the eight highest-volume agencies here.
The file is active: 17 of 25 records date from 2023 or later.
The programme is broad: 8 distinct indication wordings are recorded for talazoparib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
3 of these 25 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess talazoparib, in 2019; AIFA (Italy) did not open a file until 24 Apr 2025 — a wide spread of 5.8 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 11 of 24 dated records fall in 2024 alone.
Restriction is doing real work here: 5 of 20 decisive outcomes narrowed talazoparib to a subgroup rather than accepting or refusing it outright, at NICE (England), NYE METODER (Norway) and TLV (Sweden).
9 of the 13 agencies here assessed talazoparib more than once, TLV (Sweden) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
talazoparib has been through 13 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for talazoparib reads 8 recommended, 7 not recommended, 5 restricted and 2 no benefit, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NICE (England) | 11 Feb 2026 | NICE TA1130 | published appraisal | source |
| TLV (Sweden) | 25 Nov 2025 | Talzenna ingår i högkostnadsskyddet med utökad förmån | restricted subsidy | source |
| AIFA (Italy) | 24 Apr 2025 | Talzenna è indicato in combinazione con enzalutamide per il trattamento di pazienti adulti con cancro della prostata met… | innovative status not granted · reimbursed class H | source |
| ZIN (Netherlands) | 12 Mar 2025 | Advies - vergoed talazoparib (Talzenna®) met enzalutamide voor de behandeling van uitgezaaide prostaatkanker | reimbursed | source |
| SMC (Scotland) | 10 Mar 2025 | In combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically i… | accepted | source |
20 further decisions for talazoparib, across 12 agencies, are not shown here. They include the most recent record on file, 11 Aug 2026 from AIFA (Italy); its outcome is in the subscriber dataset. They link to 18 further source documents.
Related molecules
- atezolizumab — same ATC class L01X — Antineoplastics
- olaparib — same ATC class L01X — Antineoplastics
- durvalumab — same ATC class L01X — Antineoplastics
- aflibercept — same ATC class L01X — Antineoplastics
- osimertinib — same ATC class L01X — Antineoplastics
- venetoclax — same ATC class L01X — Antineoplastics
Coverage: 25 decisions for talazoparib from 13 agencies, 2019 to 2026. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.